Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- N/A
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
- Status
- COMPLETED
- Phase
- PHASE2
sdAb-based TRNT of Multiple Myeloma: a Feasibility Study
- Status
- COMPLETED
- Phase
- NA
A Registry Study of Participants With Multiple Myeloma in Latin America
- Status
- COMPLETED
- Phase
- N/A
Physical Activity for Myeloma Autograft Longitudinal Study
- Status
- TERMINATED
- Phase
- NA
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE4
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE3
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
- Status
- TERMINATED
- Phase
- PHASE2